Background/Aims: SNHG6 (Small Nucleolar RNA Host Gene 6) is a novel non-coding RNA (ncRNA) and its cellular function is largely unknown. Methods: Cell Counting Kit-8 (CCK-8) cell growth assay, colony formation and flow cytometry were used to determine colorectal cancer cell proliferation, cell cycle progression and apoptosis in vitro. The xenograft tumor formation assay in nude mice was established to evaluate tumor growth in vivo. RNA immunopreciptation (RIP) analysis was performed to examine whether SNHG6 could bind to EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit), and chromatin immunoprecipitation (ChIP) assay was conducted to examine whether SNHG6 could repress p21 transcription by recruiting EZH2 to the p21 promoter. Results: Here we found that SNHG6 was upregulated and its expression levels were positively correlated with advanced tumor stage in colorectal cancer. Survival analysis suggested that higher expression of SNHG6 predicted poor prognosis in patients with colorectal cancer. Functional studies indicated that SNHG6 could promote cell proliferation via a direct suppression of p21 expression in colorectal cancer cells. Moreover, SNHG6 repressed p21 transcription through recruiting EZH2 to the p21 promoter in colorectal cancer cells. Conclusion: Taken together, our study demonstrates that SNHG6 promotes tumor growth via repression of p21 in colorectal cancer, which may provide a promising target for novel anticancer therapeutics.
Introduction
Colorectal cancer (CRC) is one of the most frequent malignancies in the world and the leading cause of cancer-related mortality [1, 2] . CRC is a highly heterogeneous disease with diverse genetic and clinical manifestations which can have significant impacts on therapeutic outcomes [3] [4] [5] . Still, the prognosis of colorectal cancer patients is poor due to the cancer recurrence and distant metastasis despite treatment advances over the past decades [1, 3, Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry reaction volumes. In brief, each reaction was comprised of 2μl of the cDNA solution, 10μl of SYBR® Premix Ex TagTM (2×), 1.6μl of primers, 0.4μl of ROX Reference Dye II and 6μl of nuclease-free water. All qPCR reactions were performed on ABI 7300 Real-Time PCR System (Applied Biosystems, USA). (6) Gene-specific amplification was confirmed by a single band in 2% agarose gel electrophoresis stained with ethidium bromide. PCR efficiency of SNHG6 and GAPDH are 99.4% and 98.8%, respectively. (7) Data were analyzed by Quantification Software version 2.1 (Applied Biosystems, USA). The threshold was defined as the fractional cycle number at which the fluorescence exceeded the given threshold and was calculated using SDS Relative Quantification Software version 2.1 using the automatic baseline setting. The experiments were performed independently three times. Comparisons between groups were performed with Student's t-test statistical analysis was carried out using IBM SPSS Statistics 19 software (IBM Corp., Armonk, NY, USA).
Western blot analysis
Western blot analysis was performed as previously described [22] . Briefly, cells were lysed in cold lysis buffer, proteins (20-30μg) were resolved on SDS-PAGE, transferred onto PVDF membranes, and probed with antibodies to p21 (10355-1-AP, Proteintech), EZH2 (21800-1-AP, Proteintech), H3K27me (ab192985, Abcam) and GAPDH (sc-32233, Santa Cruz Biotechnology) at 4°C overnight. Detection was performed with the SuperSignal West Femto Maximum Sensitivity Substrate Trial Kit (Pierce, Rockford, IL, USA). Detection was carried out with the SuperSignal West Femto Maximum Sensitivity Substrate Trial Kit (Pierce, Rockford, IL, USA). The band images were digitally captured and quantified with a FluorChem FC2 imaging system (Alpha Innotech, San Leandro, CA, USA).
Immunohistochemistry
This study was approved by the Research Ethics Committee of Zhengzhou University. Written informed consents were obtained from all patients who provided samples. Colorectal cancer samples were collected at the time of diagnosis from the First Affiliated Hospital of Zhengzhou University. Immunohistochemistry analysis was performed as previously described. The relative protein expression was evaluated by the average percentage of positive cells (number of positive cells ×100/total number of cells) in 5 different random microscopic fields in each tumor sample.
RNA Immunoprecipitation (RIP) Assay
RIP experiments were performed using the Magna RIP™ RNA-Binding Protein Immunoprecipitation Kit (Millipore, Billerica, MA, USA) following the manufacturer's instructions. Antibodies for RIP-assay were EZH2 (21800-1-AP, Proteintech) or normal IgG, (ab199376, Abcam).
Chromatin Immunoprecipitation (ChIP) Assay
The ChIP assays were performed as previously reported [23] . The ChIP assay kit (Upstate Biotechnology, Inc., Lake Placid, NY) was used as recommended by the manufacturer. Briefly, approximately 1.0×10 7 cells were fixed with 1% formaldehyde for 10 min at room temperature, followed by washing with 20ml of cold 1×PBS twice and harvested by scraping. Cells were then lysed in 1 mL of SDS Lysis Buffer containing Protease Inhibitor Cocktail II. The cell lysate was sonicated on wet ice four times for 15 seconds each time with 15-second intervals to obtain chromatin fragments of about 200-1000 bp nucleotides. Insoluble materials were removed by centrifugation at 12, 000×g at 4°C for 10 min. Each 100 µL supernatants were diluted with 900 µL of ChIP dilution buffer and preincubated with Protein G agarose at 4°C for 1 hour, and then pelleted agarose by brief centrifugation and removed 10 µL (1%) of the supernatant as Input. Supernatants were incubated at 4°C overnight with 5 µg of EZH2 (21800-1-AP, Proteintech), H3K27me (ab192985, Abcam) or normal IgG, (ab199376, Abcam) incubated overnight at 4°C with rotation, and then added 60 µL of Protein G Agarose to each tube and incubated for 1 hour at 4°C with rotation. After washing with a washing buffer, the immunoprecipitates were eluted and reverse cross-linked by incubation overnight at 65°C in elution buffer. DNA was then purified with a PCR purification kit (Qiagen, Hilden, Germany). Immunoprecipitated DNAs were analyzed by quantitative real-time PCR. Xenograft tumor formation Xenograft tumor formation assay were performed as previously described [20] . Briefly, the BALB/c (6-8 weeks old) athymic nude mice were purchased from Vital River Laboratory Animal Technology (Charles River Laboratories, Beijing, China). The mice were subcutaneously injected in the flank regions with 1.0 × 10 6 cells in 0.1 mL of PBS. The tumor size was measured twice a week with calipers. The tumor volume was calculated with the formula: (Length × Width 2 )/2. Four weeks after implantation, mice were euthanized by asphyxiation in a CO 2 chamber and tumors were excised and examined. All procedures were conducted in accordance to Animal Care and Use Committee guidelines of Zhengzhou University.
Analysis of microarray data
Oncomine cancer microarray database (http://www.oncomine.org) was used to study the gene expression of SNHG6 in colorectal cancer samples. Gene expression data were also obtained from NCBI Gene Expression Omnibus (GEO) database (accession numbers: GSE8671, GSE9348, GSE5206, GSE9689 and GSE20916), and SNHG6 expression data were log transformed, median centered per array, and the standard deviation was normalized to one per array. The co-expression analysis of SNHG6 and p21 in five colorectal cancer datasets (TCGA, GSE14333, GSE37892, GSE20916 and GSE18105) was analyzed through querying the open database ChIPBase v2.0 and the R2 Genomics Analysis and Visualization Platform (http:// r2.amc.nl). The univariate survival analysis within the colorectal cancer data set of the GSE16011 (n=226) was performed using the Kaplan-Meier analysis module of the R2 microarray analysis and visualization platform.
Statistical analysis
All data were expressed as mean ± standard error of the mean (SEM). Between groups and among groups comparisons were conducted with Student t test and ANOVA, respectively. Mann-Whitney U test is used for nonparametric variables. The association analysis of SNHG6 expression and clinical characteristics was estimated by Chi-square or Fisher's two-tailed exact test. Statistical analysis was performed using GraphPad Prism software version 4.0 (PRISM4) (GraphPad Software Inc, LaJolla, CA), and p<0.05 was considered significant.
Results

SNHG6 is overexpressed in colorectal cancers and higher SNHG6 expression predicts a worse progression-free survival
To address the role of SNHG6 in colorectal cancer development, we examined the expression of SNHG6 in colorectal cancer. First, we evaluated the expression level of SNHG6 mRNA in colorectal cancers by querying the public available ONCOMINE database (www. oncomine.org) [24] . Five colorectal cancer microarray expression datasets were analyzed. The results indicated that the expression of SNHG6 mRNA is significantly higher in colorectal cancer than that in non-tumor colorectal tissues in these microarray studies. Fold increase of the levels of SNHG6 mRNA in GSE8671, GSE9348, GSE5206, GSE9689 and GSE20916 were 1.97, 3.06, 2.14, 1.91 and 2.42, respectively ( Fig. 1A-1E) . Next, the expression of SNHG6 in 66 colorectal cancer tissues and 15 non-tumor colon tissues were examined by real-time PCR. The results showed that SNHG6 was overexpressed in our own colorectal cancer patient cohort (Fig. 1F) , which was consistent with the previous microarray gene expression studies. Moreover, the correlation between the expression pattern of SNHG6 and the clinicopathological characteristics of colorectal cancer were analyzed (Table 1) . We found no significant association between SNHG6 and age, gender, tumor location, tumor grade, distant metastases and tumor recurrence, except for tumor stage (Table 1 ). In our study, overexpression of SNHG6 was detected in 18 out of 25 patients with high-stage (III/IV) colorectal cancers (p=0.011; Table 1 ).
Furthermore, we explored the relationship between SNHG6 expression and prognosis in subjects with colorectal cancer. In our patient cohort, the univariate analysis showed that patients with higher SNHG6 expression (n=33) had much worse progression-free survival Cellular Physiology and Biochemistry
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than those with lower level of SNHG6 (n=33). The estimated five-year disease progressionfree survival rates for those of the higher and lower expression groups were 49.0% and 75.8%, respectively (P=0.011; Fig. 1G ). The public available colorectal cancer dataset (GSE14333) was used to conduct survival analysis. This analysis included 226 patients with colorectal cancer. The univariate analysis of survival was performed using the KaplanMeier analysis module of the R2 microarray analysis and visualization platform (http:// r2.amc.nl). Patients with colorectal cancer were divided into SNHG6 low expression group (SNHG6 low; n=113) and SNHG6 high expression group (SNHG6 high; n=113). The KaplanMeier analysis indicated that colorectal cancer patients with high expression of SNHG6 had worse progression-free survival than those with lower expression of SNHG6 (p=0.014; Fig.  1G ). Collectively, these data indicated that patients with higher expression level of SNHG6 predicted worse progression-free survival in colorectal cancer. Fig. 2A , the expression of SNHG6 in colorectal cancer cell lines was relative higher than that in NCM460, a normal human colon mucosal epithelial cell line (*, p<0.05). We then chose SW480 and HT-29 cell lines for the following studies. SW480 and HT-29 cell lines with knockdown of the endogenous SNHG6 expression were established by lentiviral transduction (Fig. 2B) . The expression of SNHG6 mRNA was significantly repressed by SNHG6 specific shRNAs (*, p<0.05). Secondly, the cell proliferation was examined by CCK-8 cell growth assay and colony formation assay. CCK-8 cell growth assay indicated that the proliferation rate of both SW480 and HT-29 cells with knockdown of endogenous SNHG6 was significantly lower than that of control (*, p<0.05; Fig. 2C and 2D ). The numbers of colonies of vector control, SNHG6-shRNA1 and SNHG6-shRNA2 group in SW480 cells were 107.6 ± 12.4, 76.7 ± 10.1 and 71.7 ± 11.5, respectively (*, p<0.05, Fig. 2E ). Similar colony formation results were also got from HT-29 cells (*, p<0.05, Fig. 2E ). Thirdly, we examined the effect of overexpression of SNHG6 on cell proliferation in SW480 and HT-29 cells. Both CCK-8 cell growth assay ( Fig. 2F and 2G ) and colony formation assay (Fig. 2H) showed that overexpression of SNHG6 enhanced the cell proliferation of SW480 and HT-29 cells (*, p<0.05).
We further assessed whether SNHG6 could affect DNA synthesis by BrdU incorporation assay in SW480 cells. The results showed that knockdown of SNHG6 dramatically inhibited SW480 cellular DNA synthesis (*, p<0.05, Fig. 3A) . Furthermore, the effects of SNHG6 on cell cycle progression and cell death were examined in colorectal cancer cells. As shown in Fig. 3B , in the cells with repressed expression of SNHG6, there was a significant increase in the proportion of G1 phase cells and a decrease in S phase cells (*, p<0.05). It could thus be inferred that knockdown of endogenous SNHG6 might cause cell cycle arrest in G1 phase in colorectal cells. Cell death was assessed by Annexin V/PI staining assay. Results showed that knockdown of endogenous SNHG6 expression didn't cause cell death in colorectal cancer cells (NS, not significant; Fig. 3C ). Lastly, we examined the effect of overexpression of SNHG6 on DNA synthesis by BrdU incorporation assay in SW480 and HT-29 cells. Results showed that overexpression of SNHG6 dramatically enhanced DNA synthesis in colorectal cancer cells (*, p<0.05; Fig. 3D ). Collectively, these results suggested that SNHG6 promoted colorectal cancer cell proliferation in vitro. 
SNHG6 promotes cell growth of colorectal cancer cells in vivo
We further performed in vivo xenograft tumor assay to validate the above findings. SW480 cells with stable expression of SNHG6-shRNAs or vector control were injected subcutaneously into three groups of nude mice. As shown in Fig. 4A , tumors derived from SNHG6-shRNAs group grew significant slowly than those from the vector control group as assessed by tumor volume. The mean tumor volume of vector control, SNHG6-shRNA1 and SNHG6-shRNA2 group were (0.48 ± 0.06) cm 3 , (0.20 ± 0.06) cm 3 and (0.24 ± 0.07) cm 3 after four weeks, respectively (*, p<0.05). The average tumor weight of vector control, SNHG6-shRNA1 and SNHG6-shRNA2 group were (0.51 ± 0.05) g, (0.21 ± 0.02) g and (0.22 ± 0.03) g, respectively (*, p<0.05, Fig. 4B ). Ki67 staining assay showed that the Ki67 positive tumor cells was much less in SNHG6-shRNAs groups as compared with the vector control group (*, p<0.05, Fig. 4C ). In addition, the effect of SNHG6 on cellular apoptosis was explored by cleaved caspase-3 immunochemical staining. However, no significances were found between SNHG6-shRNAs group and control group (NS, not significant; Fig. 4D) . Collectively, these results demonstrated that SNHG6 promoted cell growth of colorectal cancer in vivo. 
SNHG6 inhibits p21 expression in colorectal cancer cells
The human cell cycle inhibitor p21 plays a critical role in the tumorigenesis and progression of colorectal cancer [25] . In our study, we found that p21 expression was suppressed by SNHG6 in colorectal cancer cells. First, we examined the changes of p21 mRNA by real-time PCR after knockdown of endogenous SNHG6 in two different colorectal cancer cell lines SW480 and HT-29. The results demonstrated that the expression of p21 was significantly higher in cells transduced with SNHG6-shRNAs than that of cells transduced with scramble control (*, p<0.05, Fig. 5A ). Second, the protein change of p21 was evaluated by western blot. As shown in Fig. 5B , the expression of p21 was dramatically increased in both SW480 and HT29 cells after knockdown the endogenous SNHG6. We also examined the protein changes of p21 in the xenograft tumor tissues by immunohistochemistry analysis. As compared with scramble control group, p21 expression was significant higher in SNHG6-shRNA1 group (Fig. 5C) . Then, the co-expression of SNHG6 and p21 in five colorectal cancer datasets (TCGA, GSE14333, GSE37892, GSE20916 and GSE18105) was analyzed through querying the open database ChIPBase v2.0 and the R2 Genomics Analysis and Visualization Platform (http://r2.amc.nl). The results showed a negative relationship between SNHG6 and p21 in colorectal cancers (TCGA, r: -0.377, p=1.2E-12; GSE14333, r: -0.265, p=4.2E-07; GSE37892, r: -0.358, p=2.9E-05; GSE20916, r: -0.304, p=2.0E-04; and GSE18105, r: -0.763, p=2.2E-22; Fig. 5D ).
EZH2 is the catalytic subunit of PRC2, and which plays important roles in catalyzing trimethylation of histone H3 at lysine 27 (H3K27me3) and repressing gene transcription [26, 27] . It has been previously reported that lncRNAs could bind to EZH2 and epigenetically silence the downstream target genes [26, 28] . We therefore performed RNA immunopreciptation (RIP) analysis to examine whether SNHG6 could bind to EZH2. As shown in Fig. 5E , the Fig. 5E ). The GAPDH was used as a negative control. Studies have shown that SNHG6 could bind with EZH2 in colorectal cancer cells. Therefore, we examined whether SNHG6 could repress p21 transcription by recruiting EZH2 to the p21 promoter. Chromatin immunoprecipitation (ChIP) assays in SW480 cells were conducted. The results revealed that EZH2 could directly bind to p21 promoter regions and induce H3K27me3 modification in SW480 cells. As compared to control cells, knockdown of SNHG6 significantly decreased the binding of EZH2 and H3K27me3 levels in p21 promoters (*, p<0.05, Fig. 5F ). These results suggest that SNHG6 repressed p21 transcription through recruiting EZH2 to the p21 promoter in colorectal cancer cells. 
SNHG6 promotes cell proliferation via repression of p21 in colorectal cancer
Next, we investigated whether SNHG6 promoted cell proliferation by repression of p21 in colorectal cancer cells. To this end, the endogenous p21 was knocked down in SW480 cells with stable expression of SNHG6-shRNAs. Then cell growth assay, cell cycle analysis and colony formation assay were performed. As a result, cell growth assay demonstrated that knockdown of SNHG6 significantly suppressed cell proliferation; however, this growth suppression effect of SNHG6 knockdown was compromised by repression of p21 in colorectal cancer cells (*, p<0.05, Fig. 6A ). Cell cycle analysis showed that in cells with repressed expression of SNHG6, there was a significant increase in the proportion of G1 phase cells and a decrease in the proportion of S phase cells, however, this changes could be reversed by inhibition of p21 (*, p<0.05, Fig. 6B ). The colony numbers of vector control group, SNHG6-shRNA1 group, SNHG6-shRNA1+p21-shRNA1 and SNHG6-shRNA1+p21-shRNA2 group were (105.0±7.2), (72.3±3.5), (94.0±9.2) and (99.7±4.5), respectively (*, p<0.05, Fig. 6C ). We further performed in vivo xenograft tumor assay to validate the above findings. As shown in Fig. 6D , knockdown of SNHG6 suppressed the tumor growth; however, this tumor suppressive effect conferred by SNHG6-shRNA1 was impaired after knockdown of endogenous p21 expression. The mean tumor volume of vector control, SNHG6-shRNA1 and SNHG6-shRNA1+ p21-shRNA1 group were (0.51 ± 0.04) cm 3 , (0.25 ± 0.06) cm 3 and (0.45 ± 0.06) cm 3 after four weeks, respectively (*, p<0.05, Fig. 6D ). The average tumor weight of Co-expression analysis of SNHG6 and p21 in TCGA colorectal cancer microarray datasets using the gene correlation module of the R2 microarray analysis and visualization platform. E. RIP analysis was performed to examine whether SNHG6 could bind to EZH2 in SW480 cells. The GAPDH was used as a negative control. F. The binding of EZH2 to the p21 promoter was examined by ChIP analysis. All experiments were performed in triplicate; Scale bars = 50 µm. bars, s.e.m.; *, p<0.05. Fig. 6E) . Similarly, the Ki67 positive tumor cells were reduced after knockdown of SNHG6, and this changes could be reversed by inhibition of p21 (*, p<0.05, Fig. 6F ). In summary, these results suggested that SNHG6 promoted cell proliferation via repression of p21 in colorectal cancer.
Discussion
The development and advancement of next-generation sequencing (NGS) technologies to various cancers has revealed thousands of ncRNAs has been revealed whose aberrant expression is associated with different cancer types [29] [30] [31] . An increasing number of studies indicate that diverse ncRNAs play a critical role in malignant transformation [32, 33] . SNHG6 is a novel snoRNA host gene [34, 35] , but its cellular functions are largely unknown. Aberrantly expression of SNHG6 has been detected in hepatocellular carcinoma and gastric cancer [34, 36, 37] . SNHG6 functions as a competing endogenous RNA to promote cancer progression [34, 36] and regulates ZEB1 expression by competitively binding miR-101-3p and interacting with UPF1 in hepatocellular carcinoma [37] . In addition, SNHG6 is associated with poor prognosis and enhanced tumor growth and epithelial-mesenchymal transition via suppressing p27 and sponging miR-101-3p in gastric cancer [38] . We here showed that SNHG6 was overexpressed in colorectal cancers and high level of SNHG6 was associated with advanced tumor stage in colorectal cancers, which is in consistent with the above findings. Functional studies demonstrated that SNHG6 promoted colorectal cancer cell growth in vitro and in vivo. These data suggested that SNHG6 might have an oncogenic role in tumorigenesis of colorectal cancer.
The cyclin-dependent kinase inhibitor p21 could inhibit cell cycle progression by suppression of CDK2 activity [19, 39, 40] , and its role in the tumor development and progression has been widely studied [41, 42] . It has been suggested that p21 may act as a tumor suppressor in colorectal cancer [43, 44] . Loss of expression or function of p21 has been implicated in the genesis or progression of a variety of human cancers [13, 41, 45] . In the present study, we showed that p21 expression could be inhibited by SNHG6 in colorectal cancer cells, and the repression of p21 was essential for SNHG6 to promote tumor cell growth in colorectal cancer. Hence, we come to the conclusion that SNHG6 promotes colorectal cancer cell growth by repressing transcription of p21, which is in line with previous studies.
With the progression of studies about lncRNAs, more and more ncRNAs have been found to play a critical role in tumor development and progression, however, the underlying molecular mechanisms underlying the effects of ncRNA are largely unknown [7] . These RNAs may work in gene regulatory networks as signals, decoys, guides or scaffold [46] [47] [48] , and coordinate histone modifications by binding to various histone modification enzymes such as PRC2, which is a methyltransferase for H3K27me3 and is involved in the repression of gene transcription [49] [50] [51] . EZH2 is a catalytic subunit of PRC2 [52] . Some ncRNAs could bind with EZH2 to epigenetically inhibit downstream target genes [49] . Our data showed that SNHG6 repressed p21 transcription through recruiting EZH2 to the p21 promoter in colorectal cancer cells (Fig. 7) , implicating the important role of EZH2 in colorectal cancer development.
Conclusion
Our study demonstrates that aberrantly expression of SNHG6 promotes cell growth through downregulation of p21 in colorectal cancer cells. Moreover, SNHG6 repressed p21 transcription by recruiting EZH2 to the p21 promoter. Survival analysis reveals that colorectal cancer patients with high SNHG6 expression have a poor progress-free survival. Taken together, our study not only yields a better understanding of the role of SNHG6 in colorectal tumorigenesis and cancer aggression, but also provides a promising target for novel anticancer therapeutics. 
